Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Oncomed Pharmaceuticals Inc
Oncomed Pharmaceuticals

Oncomed Pharmaceuticals patents


Recent patent applications related to Oncomed Pharmaceuticals. Oncomed Pharmaceuticals is listed as an Agent/Assignee. Note: Oncomed Pharmaceuticals may have other listings under different names/spellings. We're not affiliated with Oncomed Pharmaceuticals, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "O" | Oncomed Pharmaceuticals-related inventors


Immunotherapy with binding agents

The present invention provides agents, such as soluble receptors, antibodies, and small molecules that modulate the immune response. In some embodiments, the agents activate or increase the immune response to cancer and/or a tumor. In some embodiments, the agents inhibit or suppress the immune response to cancer and/or a tumor.... Oncomed Pharmaceuticals

Compositions and methods for treating and diagnosing cancer

The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cells. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin... Oncomed Pharmaceuticals

Rspo binding agents and uses thereof

The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins,... Oncomed Pharmaceuticals

Methods and monitoring of treatment with a dll4 antagonist

Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.... Oncomed Pharmaceuticals

Combination therapy for treatment of cancer

Described herein are combination therapies for the treatment of cancer and other diseases. In one aspect, the methods described herein for the treatment of cancer and other diseases comprise administering an RSPO-LGR pathway inhibitor in combination with a mitotic inhibitor.... Oncomed Pharmaceuticals

Immunotherapy with binding agents

Binding agents that modulate the immune response are disclosed. The binding agents may include antibodies, soluble receptors, and/or polypeptides. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.... Oncomed Pharmaceuticals

Rspo3 binding agents and uses thereof

The present invention relates to RSPO-binding agents, particularly RSPO3-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO3 proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity... Oncomed Pharmaceuticals

Rspo1 binding agents and uses thereof

The present invention relates to RSPO-binding agents, particularly antibodies that specifically bind human RSPO1. Also described are methods of treating cancer and other diseases, comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient in need thereof.... Oncomed Pharmaceuticals

Combination therapy for treatment of cancer

The present invention provides methods comprising combination therapy for treating cancer. Wnt pathway inhibitors in combination with mitotic inhibitors administered in a staggered or sequential dosing manner for the treatment of cancer and other diseases.... Oncomed Pharmaceuticals

Frizzled-binding agents and uses thereof

Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using... Oncomed Pharmaceuticals

Wnt antagonists and methods of treatment and screening

The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and... Oncomed Pharmaceuticals

Notch binding agents and antagonists and methods of use thereof

The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as... Oncomed Pharmaceuticals

Notch1 receptor binding agents and methods of use thereof

The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand... Oncomed Pharmaceuticals

Vegf/dll4 binding agents and uses thereof

The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or... Oncomed Pharmaceuticals

Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent

Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.... Oncomed Pharmaceuticals

Immunotherapy with binding agents

The present invention provides agents, such as soluble receptors, antibodies, and small molecules that modulate the immune response. In some embodiments, the agents activate or increase the immune response to cancer and/or a tumor. In some embodiments, the agents inhibit or suppress the immune response to cancer and/or a tumor.... Oncomed Pharmaceuticals

Methods for treating cancer with notch1 antiboides

The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of an anti-Notch 1 antibody.... Oncomed Pharmaceuticals

Notch3 antibodies and uses thereof

Novel antibodies that specifically bind human NOTCH3 are provided. Methods and kits using these antibodies to determine the level of NOTCH3 expression in tumor samples are provided.... Oncomed Pharmaceuticals

Methods for identifying and isolating cells expressing a polypeptide

The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.... Oncomed Pharmaceuticals








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Oncomed Pharmaceuticals in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Oncomed Pharmaceuticals with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###